Endocrine Abstracts

Sodium–glucose co-transporter 2 (SGLT2)-inhibitors represent a new class of drugs that inhibit glucose re-uptake in the proximal renal tubule resulting in glycosuria, with concomitant weight loss and improved glycaemic control in patients with type 2 diabetes mellitus (T2DM). Since becoming available, SGLT2 inhibitors have been implicated in over 20 reported cases of diabetic ketoacidosis or ketosis. In many cases there was an antecedent period of decreased oral intake, a...